PepGen Inc.

PepGen Inc. is a U.S.-based clinical-stage biotechnology company developing oligonucleotide therapeutics through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. The company was founded around technology spun out from the University of Oxford and MRC and is focused on advancing treatments for severe neuromuscular and neurologic diseases, including myotonic dystrophy type 1.

11.94

11.94

— PepGen Inc.
%
EDO platform technology0% Cell-penetrating peptide delivery technology used to improve oligonucleotide uptake and tissue delivery.
Lead therapeutic candidate0% PGN-EDODM1, an investigational therapy targeting the underlying cause of DM1.
Pipeline development programs0% Additional oligonucleotide candidates for severe neuromuscular and neurologic diseases.
Research and development services0% Internal discovery, preclinical testing, and clinical development activities supporting the pipeline.

PepGen does not currently have commercial customers because its programs are still in development...

  • Rare disease patientsprimary

    Patients with severe neuromuscular and neurologic diseases who would receive the therapy if approved.

  • Specialist prescribersprimary

    Neuromuscular specialists and key opinion leaders who influence treatment adoption in rare disease markets.

  • Healthcare providerssecondary

    Hospitals, clinics, and treatment centers that would administer or dispense the product.

  • Payerssecondary

    Insurers and reimbursement bodies that affect access, pricing, and uptake after approval.

  • Commercial partnersemerging

    Potential distributors, contract sales forces, or strategic collaborators outside the U.S.

PepGen is headquartered in Boston, Massachusetts, and is incorporated in Delaware, with origins in the U.K...

  • •Headquartered in Boston, Massachusetts
  • •Incorporated in Delaware after U.K. origins
  • •No current commercial infrastructure in any geography
  • •U.S. expected to be the first commercialization market
  • •Selected ex-U.S. markets may use partners or distributors

PepGen's strategy is centered on advancing its EDO platform and lead DM1 program through clinical development toward...

01
Clinical development of PGN-EDODM1short-term

The lead program is the main value driver and the basis for any future approval or commercialization.

02
Platform validation and pipeline expansionmedium-term

A broader pipeline reduces dependence on a single asset and increases the value of the EDO technology.

03
Commercialization planningmedium-term

Rare-disease launch strategy must match the size and concentration of the prescriber base.

PepGen is highly dependent on the success of a single lead candidate and on the outcome of clinical and regulatory...

critical

Dependence on PGN-EDODM1

The company states it is substantially dependent on the success of its lead product candidate.

Scope
Lead DM1 program
Materiality
high
critical

Clinical and regulatory failure

If trials do not demonstrate adequate safety or efficacy, approval and commercialization may not occur.

Scope
All product candidates
Materiality
high
critical

Financing and going-concern risk

The company expects to need additional capital and has disclosed substantial doubt about continuing as a going concern.

Scope
Corporate funding
Materiality
high
high

Single-source supplier dependence

Key components, API, and finished product manufacturing rely on limited suppliers.

Scope
Clinical and future commercial supply chain
Materiality
high
high

Intellectual property protection

The EDO platform depends on licensed patents, know-how, and enforceable IP rights.

Scope
Platform technology
Materiality
high
medium

China and third-party manufacturing exposure

Some vendors operate outside the U.S., including in China, creating BIOSECURE and transition risk.

Scope
Clinical trial materials and development services
Materiality
medium
Research and development accruals
Can shift reported operating losses between quarters
Stock-based compensation
Affects operating loss and diluted share analysis
Fair value of cash equivalents and marketable securities
Influences non-operating results
Going-concern assessment
Important for liquidity and financing risk disclosure

Neurogene Inc.

NGNE · Pharmaceutical Preparations

Edgewise Therapeutics, Inc.

EWTX · Pharmaceutical Preparations

Ocugen, Inc.

OCGN · Biological Products, (No Diagnostic Substances)

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

enGene Therapeutics Inc.

ENGN · Biological Products, (No Diagnostic Substances)

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

: 29/04/2026